Echelon Wealth Partners analyst Douglas Loe is staying bullish on clinical stage drug developer Antibe Therapeutics (Antibe Therapeutics Stock Quote, … [Read more...] about Antibe Therapeutics has loads of upside, says Echelon Wealth
ate
Antibe Therapeutics has an upside of 352 per cent, Echelon Wealth says
In an update to clients Wednesday, Echelon Wealth Partners analyst Douglas Loe remains bullish on clinical stage drug developer Antibe Therapeutics … [Read more...] about Antibe Therapeutics has an upside of 352 per cent, Echelon Wealth says
Buy Antibe Therapeutics for a 318 per cent return, says Echelon Wealth
In a research update on Monday, Echelon Wealth Partners analyst Douglas Loe reiterated his “Speculative Buy” rating and $1.40 target price for … [Read more...] about Buy Antibe Therapeutics for a 318 per cent return, says Echelon Wealth
Antibe Therapeutics has huge upside, Echelon Wealth says
Antibe Therapeutics (Antibe Therapeutics Stock Quote, Chart TSXV:ATE) may keep trading sideways for a while yet but the drug developer’s ATB-346 … [Read more...] about Antibe Therapeutics has huge upside, Echelon Wealth says
Antibe Therapeutics has a 192 per cent upside, Echelon Wealth says
In a coverage launch on Thursday, Echelon Wealth Partners analyst Douglas Loe says clinical stage drug developer Antibe Therapeutics (TSXV:ATE) has … [Read more...] about Antibe Therapeutics has a 192 per cent upside, Echelon Wealth says
Antibe Therapeutics could shake up the NSAID market, says M Partners
Tiny Antibe Therapeutics (TSXV:ATE) may be set to shake up the massive NSAID market, says M Partners analyst Daniel Pearlstein. In a research report … [Read more...] about Antibe Therapeutics could shake up the NSAID market, says M Partners